{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019624","form_type":"8-K/A","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.526882+00:00","generated_at":"2026-06-07T16:20:58.858208+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Harmony files Zynerba FY2022 audited financials; net loss $35M, accumulated deficit $274.5M","bullets":["Zynerba FY2022 net loss $35.0M ($0.82 loss per share); no revenue; R&D expense $21.1M, G&A $14.2M.","Cash and equivalents $50.6M at Dec 31, 2022; sufficient to fund operations to mid-2024 per management.","Acquisition closed Oct 10, 2023; pro forma combined statements filed as Exhibit 99.3 (not included in this text).","Zynerba clinical-stage pipeline targets FXS and 22q deletion syndrome; deferred Phase 3 ASD program."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019624","json":"https://secwatch.observer/filing/0001558370-23-019624.json","markdown":"https://secwatch.observer/filing/0001558370-23-019624.md","text":"https://secwatch.observer/filing/0001558370-23-019624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023019624/0001558370-23-019624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023019624/hrmy-20231010x8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:20:58.858208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}